SCHEMBL30308307

SCHEMBL30308307

Fc1ccc2ccncc2c1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK1 P49759 1/20 0.43
DYRK1A Q13627 1/20 0.43
MAPT P10636 4/20 0.40
TNF P01375 1/20 0.40
MAPK10 P53779 3/20 0.38
HIPK2 Q9H2X6 1/20 0.38
MAOA P21397 2/20 0.37
CYP17A1 P05093 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
LOXL2 Q9Y4K0 1/20 0.36
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
HTT P42858 1/20 0.36
RAD52 P43351 1/20 0.36
ACHE P22303 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22094381 1.00 CLK1 (0.43) CLK1DYRK1AMAPTTNFMAPK10
SCHEMBL29986726 0.83 IMPDH2 (0.46) MAPTCYP3A4CYP11B2LOXL2KDM4E
SCHEMBL29987653 0.79 CCNT1 (0.45) CLK1DYRK1AMAPTTNFMAPK10
SCHEMBL22981109 0.79 CCNT1 (0.45) CLK1DYRK1AMAPTTNFMAPK10
SCHEMBL11743241 0.79 CLK1 (0.41) CLK1DYRK1AMAPTTNFMAPK10
SCHEMBL15058583 0.79 IMPDH2 (0.43) CLK1DYRK1AMAPTTNFMAPK10
SCHEMBL30709993 0.79 IMPDH2 (0.43) CLK1DYRK1AMAPTTNFMAPK10
SCHEMBL672509 0.78 CLK1 (0.54) CLK1DYRK1ATNFMAPK10HIPK2
SCHEMBL29569821 0.78 CLK1 (0.54) CLK1DYRK1ATNFMAPK10HIPK2
SCHEMBL11736162 0.76 CLK1 (0.39) CLK1DYRK1AMAPTTNFMAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459922-B2 PARP7 inhibitors GILEAD SCIENCES, INC. (US) 2025-11-04 US disclosed
CN-113923988-B Substituted arylmethyl ureas and heteroarylmethyl ureas, analogs thereof, and methods of using the same 爱彼特生物制药公司 2024-12-13 CN disclosed
EP-4161916-A1 SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2023-04-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12459922-B2 PARP7 inhibitors PARP1, PARP11, PARP2 CLK1 1040/4885DYRK1A 498/4885MAPT 2243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.